{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:12:26Z","timestamp":1790820746325,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chia Tai Tianqing Pharmaceutical Group co., Ltd","award":["phase I 2017-083"],"award-info":[{"award-number":["phase I 2017-083"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10637-022-01320-9","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T14:03:00Z","timestamp":1669644180000},"page":"60-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions"],"prefix":"10.1007","volume":"41","author":[{"given":"Zhengzhi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongnan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianying","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"5","key":"1320_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A (2017) Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol 29(5):315\u2013321","journal-title":"Curr Opin Oncol"},{"issue":"24","key":"1320_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA (2014) Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol 32(24):2531\u20132540","journal-title":"J Clin Oncol"},{"issue":"1","key":"1320_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","volume":"103","author":"B Barlogie","year":"2004","unstructured":"Barlogie B et al (2004) Treatment of multiple myeloma. Blood 103(1):20\u201332","journal-title":"Blood"},{"key":"1320_CR4","doi-asserted-by":"crossref","unstructured":"San Miguel JF, Mateos MV (2011) Can multiple myeloma become a curable disease?","DOI":"10.3324\/haematol.2011.051169"},{"issue":"5","key":"1320_CR5","first-page":"2516","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood The Journal of the American Society of Hematology 111(5):2516\u20132520","journal-title":"Blood The Journal of the American Society of Hematology"},{"issue":"1","key":"1320_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157488807779316955","volume":"2","author":"A Corso","year":"2007","unstructured":"Corso A, Varettoni M (2007) The impact of new emerging drugs in the treatment of multiple myeloma: is there still a role for PBSC transplantation? Curr Stem Cell Res Therapy 2(1):1\u201311","journal-title":"Curr Stem Cell Res Therapy"},{"issue":"23","key":"1320_CR7","first-page":"6063","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M et al (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood The Journal of the American Society of Hematology 117(23):6063\u20136073","journal-title":"Blood The Journal of the American Society of Hematology"},{"key":"1320_CR8","doi-asserted-by":"crossref","unstructured":"Anderson KC (2005) Lenalidomide and thalidomide: mechanisms of action\u2014similarities and differences. Seminars in Hematology. Elsevier","DOI":"10.1053\/j.seminhematol.2005.10.001"},{"issue":"20","key":"1320_CR9","first-page":"3049","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC (2015) Pathogenesis beyond the cancer clone (s) in multiple myeloma. Blood The Journal of the American Society of Hematology 125(20):3049\u20133058","journal-title":"Blood The Journal of the American Society of Hematology"},{"issue":"9","key":"1320_CR10","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1038\/bcj.2013.38","volume":"3","author":"A Chanan-Khan","year":"2013","unstructured":"Chanan-Khan A et al (2013) Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood cancer journal 3(9):e143\u2013e143","journal-title":"Blood cancer journal"},{"issue":"12","key":"1320_CR11","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","volume":"15","author":"D Gupta","year":"2001","unstructured":"Gupta D et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950\u20131961","journal-title":"Leukemia"},{"issue":"2","key":"1320_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","volume":"128","author":"T Hayashi","year":"2005","unstructured":"Hayashi T et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128(2):192\u2013203","journal-title":"Br J Haematol"},{"issue":"16","key":"1320_CR13","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"S Schey","year":"2004","unstructured":"Schey S et al (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22(16):3269\u20133276","journal-title":"J Clin Oncol"},{"issue":"30","key":"1320_CR14","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","volume":"27","author":"MQ Lacy","year":"2009","unstructured":"Lacy MQ et al (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27(30):5008\u20135014","journal-title":"J Clin Oncol"},{"issue":"21","key":"1320_CR15","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood.V120.21.LBA-6.LBA-6","volume":"120","author":"MA Dimopoulos","year":"2012","unstructured":"Dimopoulos MA et al (2012) Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed\/refractory MM: a phase 3, multicenter, randomized, open-label study. Blood 120(21):LBA\u20136","journal-title":"Blood"},{"issue":"21","key":"1320_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1182\/blood.V120.21.74.74","volume":"120","author":"JJ Shah","year":"2012","unstructured":"Shah JJ et al (2012) A multi-center phase I\/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed\/refractory multiple myeloma. Blood 120(21):74","journal-title":"Blood"},{"issue":"14","key":"1320_CR17","first-page":"2305","volume":"122","author":"MQ Lacy","year":"2013","unstructured":"Lacy MQ, McCurdy AR, Pomalidomide, Blood (2013) J Am Soc Hematol 122(14):2305\u20132309","journal-title":"J Am Soc Hematol"},{"issue":"Spec Feature","key":"1320_CR18","first-page":"111","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler LA (2016) Pomalyst (Pomalidomide) received a new indication for patients with relapsed and\/or refractory multiple myeloma. Am health drug benefits 9(Spec Feature):111","journal-title":"Am health drug benefits"},{"issue":"5","key":"1320_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jcph.455","volume":"55","author":"Y Li","year":"2015","unstructured":"Li Y et al (2015) Population pharmacokinetics of pomalidomide. J Clin Pharmacol 55(5):563\u2013572","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1320_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1208\/s12248-016-9877-2","volume":"18","author":"BM Davit","year":"2016","unstructured":"Davit BM et al (2016) BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements. AAPS J 18(3):612\u2013618","journal-title":"AAPS J"},{"issue":"5","key":"1320_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/j.1365-2125.2010.03757.x","volume":"70","author":"E Ramirez","year":"2010","unstructured":"Ramirez E et al (2010) Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic classification system. Br J Clin Pharmacol 70(5):694\u2013702","journal-title":"Br J Clin Pharmacol"},{"key":"1320_CR22","doi-asserted-by":"crossref","unstructured":"Colon-Useche S et al (2015) Investigating the discriminatory power of BCS-biowaiver in vitro methodology to detect bioavailability differences between immediate release products containing a class I drug. Molecular pharmaceutics. 12:3167\u201331749","DOI":"10.1021\/acs.molpharmaceut.5b00076"},{"key":"1320_CR23","unstructured":"National Medical Products Administration. Technical guidelines for the study of bioequivalence of chemical generic drugs in human body with pharmacokinetic parameters as the end point criteria (in Chinese) (2016) Available from: https:\/\/www.nmpa.gov.cn\/zhuanti\/ypqxgg\/ggzhcfg\/20160318210001633.html"},{"key":"1320_CR24","doi-asserted-by":"publisher","first-page":"108780","DOI":"10.1016\/j.intimp.2022.108780","volume":"109","author":"Z Xu","year":"2022","unstructured":"Xu Z et al (2022) A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz\u00ae in chinese healthy subjects. Int Immunopharmacol 109:108780","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1320_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/ejh.12903","volume":"99","author":"P Moreau","year":"2017","unstructured":"Moreau P et al (2017) Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis. Eur J Haematol 99(3):199\u2013206","journal-title":"Eur J Haematol"},{"key":"1320_CR26","doi-asserted-by":"crossref","unstructured":"Hoy SM, Pomalidomide: a review in relapsed and refractory multiple myeloma.Drugs, 2017.77(17): p.1897\u20131908","DOI":"10.1007\/s40265-017-0833-y"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01320-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:08:47Z","timestamp":1679404127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01320-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01320-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data related to this study were interpreted by the trial staff with complete independence from the sponsor. Haimiao Yang, Zhengzhi Liu, Tianying Chang and Qing Ren are employees of Affiliated Hospital to Changchun University of Chinese Medicine; Zhongnan Xu, Zhenyue Gao and Jinling Xue are employees of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with financial interest in or financial with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients provided informed consent before initiating the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This trial is registered at the Chinese Clinical Trial website (, CTR20191514 and CTR20171422).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Chinese clinical trial registry"}}]}}